Cargando…

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Therapeutic targeting of CDK7 has proven beneficial in preclinical studies, yet the off-target effects of currently available CDK7 inhibitors make it difficult to pinpoint the exact mechanisms behind MM cell death mediated by CDK7 inhibition. Here, we show that CDK7 expression positively correlates...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Yao, Ng, Jessica Fong, Park, Woojun Daniel, Samur, Mehmet, Morelli, Eugenio, Encinas Mayoral, Jessica, Chyra, Zuzana, Xu, Yan, Derebail, Sanika, Epstein, Charles, Nabet, Behnam, Chesi, Marta, Gray, Nathanael S., Young, Richard A., Kwiatkowski, Nicholas, Mitsiades, Constantine, Anderson, Kenneth C., Lin, Charles Y., Munshi, Nikhil C., Fulciniti, Mariateresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Lymphoid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315622/ https://www.ncbi.nlm.nih.gov/pubmed/36877894 http://dx.doi.org/10.1182/blood.2022018885

Ejemplares similares

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM
por: Stong, Nicholas, et al.
Publicado: (2023)

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma
por: Ansari-Pour, Naser, et al.
Publicado: (2023)

Peripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma
por: Edwards, Camille V., et al.
Publicado: (2022)

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
por: Gupta, Vikas A., et al.
Publicado: (2021)

Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma
por: Merz, Maximilian, et al.
Publicado: (2022)

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
por: Chari, Ajai, et al.
Publicado: (2020)

Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL
por: Yano, Max, et al.
Publicado: (2022)

Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma
por: Maziarz, Richard T., et al.
Publicado: (2022)

Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas
por: Koh, Min Jung, et al.
Publicado: (2022)

Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma
por: Little, Jessica S., et al.
Publicado: (2022)

Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH
por: Yan, Yuting, et al.
Publicado: (2022)

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
por: Tatarczuch, Maciej, et al.
Publicado: (2023)

TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy
por: Chen, Jing, et al.
Publicado: (2023)

BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5
por: Oien, Derek B., et al.
Publicado: (2023)

Sézary syndrome patient–derived models allow drug selection for personalized therapy
por: Gallardo, Fernando, et al.
Publicado: (2022)

Aberrant expression of GOLM1 protects ALK(+) anaplastic large cell lymphoma from apoptosis by enhancing BCL-X(L) stability
por: Zi, Zhenguo, et al.
Publicado: (2023)

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
por: Thijssen, Rachel, et al.
Publicado: (2022)

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
por: Tedeschi, Alessandra, et al.
Publicado: (2021)

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor
por: Gomez, Eliana B., et al.
Publicado: (2023)

Sézary syndrome originates from heavily mutated hematopoietic progenitors
por: Harro, Carly M., et al.
Publicado: (2023)

Retrospective characterization of nodal marginal zone lymphoma
por: Stuver, Robert, et al.
Publicado: (2023)

Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
por: Lemoine, Jean, et al.
Publicado: (2023)

Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
por: Aubrais, Raphaelle, et al.
Publicado: (2022)

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
por: Cherng, Hua-Jay J., et al.
Publicado: (2022)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

Epstein Barr virus–positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo
por: Zhang, Xiaoshan, et al.
Publicado: (2022)

TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
por: Johnson, William T., et al.
Publicado: (2023)

Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia
por: Ferguson, Daniel C., et al.
Publicado: (2022)

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma
por: Bewicke-Copley, Findlay, et al.
Publicado: (2022)

A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma
por: van Bladel, Diede A. G., et al.
Publicado: (2023)

Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma
por: Thomas, Nicole, et al.
Publicado: (2023)

SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma
por: Wrench, David, et al.
Publicado: (2011)

Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma
por: Silva, Ana, et al.
Publicado: (2021)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021)

COVID-19 in patients with CLL: how can we change the odds?
por: Herishanu, Yair, et al.
Publicado: (2021)

The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5
por: Manfroi, Benoît, et al.
Publicado: (2021)

Nras(Q61R/+) and Kras(−/−) cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors
por: Wen, Zhi, et al.
Publicado: (2021)

Toward prevention of childhood ALL by early-life immune training
por: Hauer, Julia, et al.
Publicado: (2021)

Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia
por: Duault, Caroline, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e2f1pm8p61t0r783aqsklnpokh